Beximco Pharma Explained

Beximco Pharmaceuticals Ltd
Type:Limited
Key People:Iqbal Ahmed (Managing Director)
Industry:Pharmaceutical
Foundation:1980
Traded As:
Location:Dhanmondi, Dhaka, Bangladesh
Revenue: (2023)[1]
Operating Income: (2023)
Net Income: (2023)
Num Employees:4,523 (2019)[2]

Beximco Pharmaceuticals Ltd, also known as Beximco Pharma (stylised as BEXIMCO PHARMA) is a Bangladeshi multinational pharmaceutical company.[3] It is a part of Bangladesh Export Import Company Limited (BEXIMCO).[4]

History

Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of United States.[5] Today, Beximco Pharma manufactures and markets its own branded generics for several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and international markets. It was the first drug company from Bangladesh to sell its products in the US.[6]

In May 2020, the company introduced the world's first generic remdesivir for COVID-19 treatment.[7] [8] [9] Beximco Pharma became the first company to obtain production and marketing authorization for molnupiravir, the first and only specific oral anti-covid drug in Bangladesh along with Eskayef Pharmaceuticals.[10] [11] Beximco Pharma's branded generic version of molnupiravir is being marketed as Emorivir.[12]

Factories

Beximco Pharma manufacturing facilities are spread across a 20acres site located in Dhaka, Bangladesh.[13] The facilities consist of a number of purpose-built plants, including a new Oral Solid Dosage (OSD) plant. The site includes manufacturing facilities as well as a research laboratory and a number of warehouses. The plant and machinery of the facilities were designed, produced and installed by partners from Germany, Switzerland, Sweden, Italy and the United Kingdom, amongst others.

Exports

In August 2007, Beximco exported its medicines to the Philippines, the 5th country of the 10-member Association of South East Asian Nations (ASEAN) to import Beximco's drugs.

External links

Notes and References

  1. News: Beximco Pharmaceuticals Ltd. . 18 January 2024 . WSJ.
  2. Web site: Beximco Pharma Annual Report 2018-19. 23 December 2019.
  3. News: BD firm plans to export version of Tamiflu . . 5 April 2006 . 8 March 2008 . dead . https://web.archive.org/web/20110606162138/http://www.dailytimes.com.pk/default.asp?page=2006%5C04%5C05%5Cstory_5-4-2006_pg5_14 . 6 June 2011 .
  4. News: Bangladesh forays into US market with Beximco Pharma. bdnews24.com. 3 October 2016.
  5. Web site: Beximco Pharma Q3 revenue up. The Pharma Letter. 3 October 2016.
  6. News: US FDA approves Beximco Pharma's blood pressure drug . Dhaka Tribune. 3 October 2016. https://web.archive.org/web/20160930225333/http://archive.dhakatribune.com/business/2015/nov/19/us-fda-approves-beximco-pharmas-blood-pressure-drug. 30 September 2016. dead.
  7. News: Beximco introduces remdesivir for Covid-19 treatment. 21 May 2020. The Daily Star. en. 24 May 2020.
  8. News: Beximco Pharma introduces world's first generic Remdesivir for COVID-19 treatment. The Financial Express. Dhaka. en. 24 May 2020.
  9. News: Siddiqui. Zeba. 5 May 2020. Exclusive: Bangladesh's Beximco to begin producing COVID-19 drug remdesivir - COO. en. Reuters. 6 March 2021.
  10. News: Pilla . Viswanath . Bangladesh drug maker Beximco launches world's first generic of Pfizer's COVID antiviral . . December 30, 2021 . June 26, 2024.
  11. News: Beximco Pharma gets license for oral anti-Covid drug . . January 20, 2022 . June 26, 2024.
  12. News: Merck’s COVID-19 pill molnupiravir hits Bangladesh markets . . June 26, 2024 . June 26, 2024.
  13. News: Beximco Pharma’s Q3 profits soar 51% . The Daily Star . April 30, 2024 . June 26, 2024.